### USER
As a busy physician, I already have a comprehensive guidance document for the attached material. I‚Äôve included the full guidance for reference.

Could you please condense this lengthy document into a one-page reference algorithm for fast memory aide and fast decision making? This will allow me to quickly access key points during patient consultations.

### ASSISTANT
Certainly. Below is a **condensed one-page reference algorithm** for **Combined Hormonal Contraception (CHC)** based on the NICE CKS guidance (August 2024). This is designed for rapid clinical use in primary care.

---

### **Combined Hormonal Contraception (CHC) ‚Äì One-Page Clinical Algorithm**  
*Based on NICE CKS (Aug 2024)*

---

#### **1. Is This the Right Patient?**  
**Age:** 13‚Äì60 years (female)  
**Methods:** Combined oral contraceptive (COC), patch, vaginal ring  
**Exclude:** Pregnancy, contraindications (see UKMEC)

---

#### **2. Medical Eligibility (UKMEC 1‚Äì4)**  
**UKMEC 3 or 4 = NOT recommended:**  
- History of VTE, stroke, MI  
- Current breast cancer  
- Migraine with aura (any age), migraine without aura + age >35  
- Hypertension: SBP ‚â•140 or DBP ‚â•90 mmHg  
- Major surgery with prolonged immobilization  
- BMI ‚â•40 kg/m¬≤ (or ‚â•35 with other risk factors)  
- Smoking ‚â•35 years and >10 cigarettes/day  
- Estrogen-dependent cancer  
- Active liver disease or liver tumour  
- Undiagnosed abnormal vaginal bleeding  

*Refer to UKMEC for full criteria.*

---

#### **3. Starting CHC**  
**Can start anytime if:**
- **Day 1‚Äì5 of cycle** ‚Üí immediate protection  
- **Any other day** ‚Üí use additional contraception (e.g., condoms) for 7 days  

**Postpartum:**  
- Non-breastfeeding: Can start Day 21 ‚Üí immediate protection  
- Breastfeeding: Avoid CHC in first 6 weeks; consider progestogen-only methods  

**Post-abortion/miscarriage:** Immediate start if <24 weeks gestation  

**Post-VTE or stroke:** Avoid CHC; use progestogen-only or LARC  

---

#### **4. Method-Specific Advice**  
| **Method**       | **Use** | **Missed/Issues** |
|------------------|-------|-------------------|
| **COC**          | Daily, 21/7 or 28-day | Missed >12 hrs (2+ pills): Use backup x 7 days |
| **Patch**        | Weekly x 3, off week 4 | Detached >24 hrs ‚Üí treat as missed |
| **Vaginal Ring** | 3 weeks in, 1 week out | Expelled >3 hrs ‚Üí wash & reinsert; backup if >3 hrs |

---

#### **5. Drug Interactions ‚Äì Key Risks**  
**Enzyme-inducing drugs (reduce efficacy):**  
- Rifampicin, rifabutin, carbamazepine, phenytoin, St John‚Äôs wort  
‚Üí Use alternative (LARC, POP, or higher-dose COC + condoms)  

**New (Aug 2024):**  
- **Tirzepatide** ‚Üí may reduce oral contraceptive efficacy (MHRA warning)  
‚Üí Consider alternative or backup method  

**GI disturbances:**  
- Vomiting <2 hrs post-pill or severe diarrhoea ‚Üí treat as missed dose  

---

#### **6. Common Issues & Management**  
- **Unscheduled bleeding:** Common in first 3 months; reassess if persistent  
- **Amenorrhoea on COC:** Likely normal; rule out pregnancy if compliant  
- **Advise:** No routine breaks; regular BP checks; smoking cessation support  

---

#### **7. Efficacy & Counselling Points**  
- **Perfect use:** <1% failure/year  
- **Typical use:** ~7% failure/year  
- **Benefits:** Regular cycles, reduced dysmenorrhoea, acne improvement, endometrial/ovarian cancer protection  
- **Risks:** Slight ‚Üë VTE (highest in first year), stroke, MI (especially with risk factors)  

---

#### **8. Patient-Centred Care**  
- Offer full range of methods (including LARC)  
- Discuss preferences, lifestyle, side effects  
- Shared decision-making essential  

---

*Sources: NICE CKS (Aug 2024), FSRH (2023a), UKMEC (2016), BNF, MHRA*  
*¬© Clarity Informatics Ltd (Agilio) ‚Äì Used under licence*

--- 

This algorithm can be printed or saved for quick reference during consultations.

### USER

Design an attractive HTML/CSS webpage with a clean, modern UI that displays all the provided information in a visually appealing layout.

### ASSISTANT
```html
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Combined Hormonal Contraception - Quick Reference</title>
  <style>
    /* Global Styles */
    body {
      font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
      background-color: #f8f9fa;
      color: #333;
      line-height: 1.6;
      margin: 0;
      padding: 0;
    }
    .container {
      max-width: 1000px;
      margin: 20px auto;
      padding: 20px;
      background: white;
      border-radius: 12px;
      box-shadow: 0 6px 18px rgba(0, 0, 0, 0.1);
    }
    header {
      text-align: center;
      margin-bottom: 25px;
      border-bottom: 1px solid #e0e0e0;
      padding-bottom: 15px;
    }
    h1 {
      font-size: 28px;
      color: #005ea5;
      margin: 0;
    }
    h2 {
      color: #005ea5;
      border-bottom: 2px solid #005ea5;
      padding-bottom: 8px;
      margin-top: 25px;
      font-size: 20px;
    }
    h3 {
      color: #2980b9;
      margin-top: 20px;
      font-size: 18px;
    }
    p {
      margin: 10px 0;
    }

    /* Algorithm Grid */
    .algorithm {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
      gap: 15px;
      margin-top: 20px;
    }
    .step {
      background: #f1f7fc;
      padding: 16px;
      border-radius: 10px;
      border-left: 4px solid #005ea5;
      box-shadow: 0 2px 6px rgba(0,0,0,0.05);
    }
    .step h3 {
      margin-top: 0;
      color: #005ea5;
    }

    /* Table Styling */
    table {
      width: 100%;
      border-collapse: collapse;
      margin: 15px 0;
    }
    th, td {
      padding: 10px;
      text-align: left;
      border-bottom: 1px solid #ddd;
    }
    th {
      background-color: #005ea5;
      color: white;
    }
    tr:nth-child(even) {
      background-color: #f9f9f9;
    }

    /* Warning Box */
    .warning {
      background-color: #fff3cd;
      border: 1px solid #ffeaa7;
      border-radius: 8px;
      padding: 12px;
      margin: 15px 0;
      font-weight: 500;
      color: #856404;
    }

    /* Footer */
    footer {
      text-align: center;
      margin-top: 30px;
      color: #666;
      font-size: 14px;
      border-top: 1px solid #e0e0e0;
      padding-top: 15px;
    }

    /* Responsive */
    @media (max-width: 768px) {
      .container {
        padding: 15px;
      }
      h1 {
        font-size: 24px;
      }
    }
  </style>
</head>
<body>
  <div class="container">
    <header>
      <h1>Combined Hormonal Contraception (CHC)</h1>
      <p><strong>Quick Reference Algorithm for Busy Clinicians</strong><br>
      Based on NICE CKS Guidance (August 2024)</p>
    </header>

    <div class="algorithm">
      <!-- Step 1 -->
      <div class="step">
        <h3>‚úÖ Patient Eligibility</h3>
        <p><strong>Age:</strong> 13‚Äì60 years (female)</p>
        <p><strong>Methods:</strong> COC, patch, vaginal ring</p>
        <p><strong>Exclude:</strong> Pregnancy, contraindications (UKMEC 3‚Äì4)</p>
      </div>

      <!-- Step 2 -->
      <div class="step">
        <h3>‚ö†Ô∏è Key Contraindications (UKMEC 3/4)</h3>
        <ul style="margin: 10px 0; padding-left: 20px;">
          <li>VTE, stroke, MI history</li>
          <li>Current breast cancer</li>
          <li>Migraine with aura (any age)</li>
          <li>HTN: SBP ‚â•140 or DBP ‚â•90</li>
          <li>BMI ‚â•40 (or ‚â•35 + risks)</li>
          <li>Smoking >10/day & age ‚â•35</li>
        </ul>
      </div>

      <!-- Step 3 -->
      <div class="step">
        <h3>üìÖ Starting CHC</h3>
        <p><strong>Day 1‚Äì5 of cycle:</strong> Immediate protection</p>
        <p><strong>Any other day:</strong> Backup x 7 days</p>
        <p><strong>Postpartum:</strong> Non-breastfeeding ‚Üí Day 21; Breastfeeding ‚Üí avoid first 6 weeks</p>
      </div>

      <!-- Step 4 -->
      <div class="step">
        <h3>üíä Method Guide</h3>
        <table>
          <tr><th>Method</th><th>Use</th></tr>
          <tr><td>COC</td><td>Daily, 21/7 or 28-day</td></tr>
          <tr><td>Patch</td><td>Weekly x 3, off week 4</td></tr>
          <tr><td>Vaginal Ring</td><td>3 weeks in, 1 week out</td></tr>
        </table>
      </div>
    </div>

    <!-- Drug Interactions -->
    <h2>üö® Drug Interactions</h2>
    <div class="warning">
      <strong>Enzyme-inducing drugs:</strong> Rifampicin, carbamazepine, phenytoin, St John‚Äôs wort ‚Äî reduce efficacy.
    </div>
    <p><strong>New (Aug 2024):</strong> <span style="color:#c0392b;">Tirzepatide</span> may reduce oral contraceptive efficacy (MHRA). Consider alternative or backup method.</p>
    <p><strong>GI disturbances:</strong> Vomiting <2 hrs post-pill or severe diarrhoea ‚Üí treat as missed dose.</p>

    <!-- Missed Doses -->
    <h2>üîÅ Missed Dose Guidance</h2>
    <table>
      <tr><th>Method</th><th>Action</th></tr>
      <tr>
        <td>COC</td>
        <td>Missed >12 hrs: Use backup x 7 days. 2+ pills missed: follow FSRH guidelines.</td>
      </tr>
      <tr>
        <td>Patch</td>
        <td>Detached >24 hrs: Replace & use backup x 7 days.</td>
      </tr>
      <tr>
        <td>Vaginal Ring</td>
        <td>Expelled >3 hrs: Reinsert & use backup if >3 hrs.</td>
      </tr>
    </table>

    <!-- Common Issues -->
    <h2>ü©∫ Common Issues & Management</h2>
    <ul>
      <li><strong>Unscheduled bleeding:</strong> Common first 3 months; reassess if persistent</li>
      <li><strong>Amenorrhoea:</strong> Likely normal; rule out pregnancy</li>
      <li><strong>Follow-up:</strong> BP checks, smoking cessation, no routine breaks</li>
    </ul>

    <!-- Efficacy & Counselling -->
    <h2>üìä Efficacy & Counselling</h2>
    <p><strong>Perfect use:</strong> <1% failure/year<br>
       <strong>Typical use:</strong> ~7% failure/year</p>
    <p><strong>Benefits:</strong> Regular cycles, reduced dysmenorrhoea, acne improvement, cancer protection</p>
    <p><strong>Risks:</strong> Slight ‚Üë VTE (highest in first year), stroke, MI (esp. with risk factors)</p>

    <!-- Patient-Centered Care -->
    <h2>ü§ù Patient-Centered Care</h2>
    <p>‚Ä¢ Offer full range of methods (including LARC)<br>
       ‚Ä¢ Discuss preferences, lifestyle, side effects<br>
       ‚Ä¢ Shared decision-making essential</p>

    <footer>
      <p>Sources: NICE CKS (Aug 2024), FSRH (2023a), UKMEC (2016), BNF, MHRA</p>
      <p>¬© Clarity Informatics Ltd (Agilio) ‚Äì Used under licence</p>
    </footer>
  </div>
</body>
</html>
```

---

### ‚úÖ Features of This Webpage:
- **Clean, modern UI** with responsive grid layout
- **Color-coded sections** for quick visual scanning
- **Mobile-friendly** design using CSS Grid and Flex principles
- **Highlighted warnings** (e.g., tirzepatide interaction)
- **Easy-to-read tables** for dosing and missed use
- **Professional typography and spacing** for clinical readability
- **Print-ready** if needed (minimal ink usage)

You can copy and save this code as an `.html` file and open it in any browser, or integrate it into an internal clinical portal or EMR system for quick reference.